American Regent Recalls Adequan Canine and Equine Injection Lots After Fiberglass Found in Vials
Key Takeaways
- •American Regent voluntarily recalled two lots each of Adequan Canine Injection for dogs and Adequan i.m. Injection for horses after fiberglass contamination was detected during routine testing.
- •No reports of injury or adverse events have been linked to the recalled medication lots as of the announcement.
- •The recalled medications are polysulfated glycosaminoglycan-based injectable treatments widely prescribed for joint dysfunction in aging dogs and performance horses.
- •The company warns that injecting products contaminated with glass particles may cause local irritation, swelling, infection, or abscesses at the injection site.
- •Consumers, veterinary hospitals, distributors, and retailers are instructed to immediately stop using the affected products and return or dispose of them properly.
A nationwide recall has been issued for select lots of veterinary joint medication after fiberglass particles were discovered floating in injection vials.
American Regent, Inc. announced the voluntary recall affecting two lots of Adequan Canine Injection, used to treat joint dysfunction in dogs, and two lots of Adequan i.m. Injection, prescribed for joint dysfunction and lameness in horses. Adequan is a polysulfated glycosaminoglycan (PSGAG)-based medication widely prescribed in veterinary practice, particularly for aging dogs with osteoarthritis and performance horses subject to repetitive joint stress. Both medications are clear, colorless to slightly yellow solutions administered via intramuscular injection.
The glass fibers were detected during routine testing conducted by the company. American Regent stated that it has not received any reports of injury or adverse events connected to the recalled lots.
In its recall notice, the company warned: "The administration of an intramuscular injectable product containing particulate matter, such as glass fibers, may result in local irritation, swelling, inflammation, injection site pain, infection, or abscesses."
Injectable product recalls involving particulate contamination are treated with urgency because foreign material introduced into muscle tissue or deeper structures can be difficult to detect and may persist long after the initial injection. Veterinary pharmaceutical recalls in the United States fall under the oversight of the FDA's Center for Veterinary Medicine, which works with manufacturers to ensure recalled products are removed from distribution channels.
Consumers who have purchased the affected product lots are urged to stop using them immediately and either discard the medication or return it to the manufacturer. Pet owners whose animals have experienced any health issues potentially linked to the recalled medication are advised to contact a veterinarian.
Veterinary hospitals, distributors, and retailers have also been instructed to return any unused product to American Regent or dispose of it appropriately.
American Regent, Inc., a subsidiary of Daiichi Sankyo Group, is a pharmaceutical manufacturer headquartered in Shirley, New York. The company produces a range of human and veterinary injectable products.
"American Regent, Inc. is committed to the safety of patients who rely on its products and is taking this precautionary action to protect public health," the company said in its statement.
The recall applies to specific lot numbers of the two products. Consumers and veterinary professionals seeking additional details about the affected lots can refer to the company's official recall notice.
Source: Fox Business
